Definium Therapeutics (NASDAQ:DFTX) Shares Climb 5.3% – Time to Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price rose 5.3% during mid-day trading on Monday. The company traded as high as $38.38 and last traded at $38.08. Approximately 1,262,536 shares were traded during trading, a decline of 44% from the average daily volume of 2,263,909 shares. The stock had previously closed at $36.17.

Analyst Ratings Changes

Several research firms have issued reports on DFTX. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Definium Therapeutics in a research report on Monday, September 14th. Canaccord Genuity Group set a $78.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. Oppenheimer restated an “outperform” rating and set a $75.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Finally, Maxim Group set a $55.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a research note on Friday, August 14th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Buy” and an average price target of $64.88.

Definium Therapeutics Stock Up 7.2%

The company has a market cap of $5.21 billion, a price-to-earnings ratio of -11.31 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The firm has a 50-day moving average price of $41.59 and a 200 day moving average price of $31.78.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Sell-side analysts predict that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Insider Activity

In other Definium Therapeutics news, CEO Robert Barrow sold 19,023 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $37.94, for a total transaction of $721,732.62. Following the transaction, the chief executive officer owned 1,494,640 shares in the company, valued at $56,706,641.60. This represents a 1.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP acquired a new position in Definium Therapeutics in the 2nd quarter valued at $138,755,000. Seven Fleet Capital Management LP bought a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $6,992,000. Arizona State Retirement System acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth $1,431,000. Stableford Capital II LLC acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth $1,277,000. Finally, Sequoia Financial Advisors LLC bought a new position in shares of Definium Therapeutics in the second quarter worth $812,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.